Latest news with #Getinge
Business Insider
3 days ago
- Business
- Business Insider
Kepler Capital Sticks to Its Hold Rating for Getinge (0GZV)
Kepler Capital analyst Oliver Reinberg maintained a Hold rating on Getinge on July 18 and set a price target of SEK225.00. The company's shares closed last Friday at SEK201.91. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Reinberg covers the Healthcare sector, focusing on stocks such as STRATEC Biomedical, Koninklijke Philips N.V., and Fresenius Medical Care AG & Co. KGaA. According to TipRanks, Reinberg has an average return of -5.5% and a 40.90% success rate on recommended stocks. Currently, the analyst consensus on Getinge is a Hold with an average price target of SEK211.67, which is a 4.83% upside from current levels. In a report released on July 18, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a SEK203.00 price target. The company has a one-year high of SEK232.20 and a one-year low of SEK164.55. Currently, Getinge has an average volume of 188.9K.
Yahoo
5 days ago
- Business
- Yahoo
Getinge AB (GNGBF) Q2 2025 Earnings Call Highlights: Strong Organic Growth and Margin ...
Organic Net Sales Growth: 4.1% in Q2 2025. Order Intake Growth: 4.4% organically. Recurring Revenue: 65% of total sales. High Margin Products: Comprise about 2/3 of sales. Adjusted Gross Profit: SEK4.183 billion. Gross Margin Increase: Up by 0.8 percentage points. Adjusted EBITDA: SEK989 million, margin improved by 0.2 percentage points to 12%. Tariff Costs: Approximately SEK110 million in Q2. Free Cash Flow: SEK0.5 billion in Q2. Net Debt: SEK11.7 billion, leverage at 1.7 times adjusted EBITDA. Cash Position: Approximately SEK1.9 billion at the end of Q2. 2025 Outlook: Organic net sales growth expected to be 2% to 5%. Warning! GuruFocus has detected 6 Warning Signs with GNGBF. Release Date: July 18, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Getinge AB (GNGBF) reported a solid quarter with net sales growing by 4.1% organically, driven by positive development across all business areas and regions. The company achieved a significant increase in sales from recurring revenue, now at 65%, and high-margin products make up about two-thirds of sales. Adjusted gross and EBITDA margins improved due to acquisitions, healthy price increases, and a positive mix, despite tariffs and currency headwinds. The financial position remains strong with financial leverage well below 2.5 times EBITDA, even after the acquisition of Paragonix. Getinge AB (GNGBF) continues to invest in new products and solutions, such as the Servo-c ventilator with neonatal options and the Zen disinfection chemistry portfolio, enhancing its market offerings. Negative Points Tariffs and currency fluctuations negatively impacted the EBITDA margin, with tariffs costing approximately SEK110 million in the second quarter. The Life Science segment experienced softer performance due to high comparative figures from the previous year. There are ongoing elevated costs related to quality improvements, particularly in the balloon pump and cardiopulmonary categories. The company faces challenges in maintaining market share in certain categories, such as intra-aortic balloon pumps, due to restrictions on actively selling and marketing these products. Despite positive trends, the company anticipates more difficult comparisons in the second half of the year, particularly in ventilator sales. Q & A Highlights Q: Can you explain the implications of tariffs and FX on your long-term guidance and whether you've found new mitigation strategies? A: Our long-term guidance is based on the current tariff situation. We haven't found new mitigation strategies but are utilizing existing productivity improvements and regional supply chain strategies. The impact of tariffs and FX is significant, but we are managing it within our existing frameworks. - Mattias Perjos, CEO Q: What are your current assumptions regarding EU tariffs, and how do you expect them to impact your full-year results? A: We currently assume a 10% EU tariff for the full year. If tariffs increase, we would need to recalibrate our calculations. We don't provide specific guidance on future tariffs or FX impacts. - Agneta Palmer, CFO Q: How is the demand for ventilators expected to evolve, and can you disclose the number of ventilators you anticipate selling this year? A: Ventilator demand remains strong, but we expect more challenging comparisons in the second half of the year. We do not disclose specific sales numbers for ventilators. - Mattias Perjos, CEO Q: Could you provide more details on the tariff payments and their regional impact? A: Tariff payments began in the second half of April, primarily affecting EU to US flows. We have taken measures to manage our supply chain in response to these tariffs. - Agneta Palmer, CFO Q: What is driving the positive development of Paragonix, and can you provide any margin details? A: The margin expansion for Paragonix is volume-driven, and it is now accretive to group margins. The growth is supported by a successful product portfolio, including the KidneyVault launch. - Mattias Perjos, CEO For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Reuters
5 days ago
- Business
- Reuters
Getinge tops profit estimates, explores ways to lessen tariff hit
July 18 (Reuters) - Getinge's ( opens new tab quarterly earnings beat market expectations on Friday, driven by organic sales growth across its business areas and regions, as the medical equipment maker seeks ways beyond pricing to mitigate the tariff impact. Shares of the Swedish group, which makes more than a third of its sales in the United States, were up nearly 7% by 0813 GMT, among top performers on Europe's benchmark STOXX 600 index (.STOXX), opens new tab. "We were once again successful in adjusting prices, but short term we have been forced to absorb most of the tariff costs," CEO Mattias Perjos said in a statement. The price increases were 2% on average, Perjos told Reuters, but said there was "a limit to how much can be done with pricing". "We are also analyzing opportunities to adapt the company's costs and supply chain over time to this new reality," he said in the statement. Among potential short-term measures, Getinge is looking at whether it can adjust some sourcing of key components or move its products' final assembly to the U.S., Canada or Mexico, depending on how the trade regulations evolve, Perjos added in the interview. Getinge's adjusted earnings before interest, taxes and amortisation rose 0.8% to 989 million Swedish crowns ($101.7 million) in the quarter. Analysts were expecting 921 million on average, a company-provided poll, opens new tab showed. The earnings beat was mainly driven by the Surgical Workflows business area, while contributions from acquisitions and price hikes supported margins, analysts from said in a note. The maker of products for surgery, intensive care and sterilisation said the core profit included a nearly 270 million crown loss caused by U.S. President Donald Trump's import duties and negative currency effects compared to last year. Getinge reiterated its 2025 guidance for organic sales growth of between 2% and 5%. ($1 = 9.7257 Swedish crowns)
Yahoo
15-07-2025
- Business
- Yahoo
Zimmer agrees to distribute Getinge products to expand ASC offering
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Zimmer Biomet has struck a deal to distribute Getinge's infection control and surgical portfolio to its ambulatory surgery center customers, the companies said Thursday. The agreement positions ASCs, facilities that provide same-day surgical care, to source implants, surgical robotics, surgical equipment, lighting and other products from a single company. Zimmer initially plans to target the U.S. before potentially expanding to other parts of the world as it ramps up efforts to grow its ASC business. Zimmer and other orthopedic companies have identified ASCs as a growth opportunity. Interest has risen as the number of ASCs has grown and Medicare reimbursement has expanded. There were almost 6,500 Medicare-certified ASCs in the U.S. as of March 2025, compared to just over 6,000 in late 2022, according to the Ambulatory Surgery Center Association. Medicare began covering total knee replacements in 2020 and total hip replacements in 2021. ASCs account for around 20% of Zimmer's U.S. sales, CEO Ivan Tornos said on an earnings call in May, up from 2% to 4% before the COVID-19 pandemic. The company forecasts that ASCs will account for 40% to 60% of sales in the next five years. Zimmer has struck deals to try to exceed the market growth rate. Partnering with Getinge could support Zimmer's ambitions by expanding its offering to ASC customers beyond orthopedic implants and surgical robotics. Jehanzeb Noor, chief strategy, innovation and business development officer at Zimmer, outlined the thinking behind the deal in a statement. 'As orthopedic surgeries increasingly migrate from traditional hospital settings to ASCs, the imperative to drive efficiency, enhance patient safety and improve clinical outcomes has never been greater,' Noor said. 'By aligning with Getinge, we're accelerating our ability to support surgeons in advancing these priorities, while shaping the future of orthopedic care.' The agreement comes about six months after Zimmer disclosed a deal to buy foot and ankle implant provider Paragon 28 for $1.1 billion. Talking at a Goldman Sachs event in June, Tornos said the Paragon 28 deal would enable cross-selling of trauma and biologic devices and give Zimmer 'a better category leadership position in ASC.' Tornos said there were 'more deals to come that are similar to Paragon 28.' Recommended Reading Zimmer touts ASC opportunity with Paragon 28 purchase Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Reuters
22-04-2025
- Business
- Reuters
Medical gear maker Getinge's core profit slightly lags forecast
April 22 (Reuters) - Swedish medical equipment maker Getinge ( opens new tab reported first-quarter core earnings slightly below market expectations on Tuesday, dragged by a decline in sales of operating tables and challenges in the Bio-Processing product category. Its adjusted earnings before interest, taxes and amortisation (EBITA) rose 19% to 1.00 billion Swedish crowns ($105.45 million) in the quarter. Analysts were expecting 1.01 billion crowns on average, a company-provided poll, opens new tab showed. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. Commenting on U.S. President Donald Trump's import duties, the company said the trade war would ultimately affect hospitals and patients the most, as tariffs distort competition and lead to higher costs. "Getinge is preparing for various scenarios and potential necessary actions, where price adjustments are one of many tools available to counteract negative effects on profitability," it added. Getinge makes more than a third of its sales in the United States. The maker of products for surgery, intensive care and sterilisation reaffirmed its 2025 guidance for organic sales growth of between 2% and 5%.
